Your browser doesn't support javascript.
loading
Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.
Wahlstrom, Justin T; Dvorak, Christopher C; Cowan, Morton J.
Afiliación
  • Wahlstrom JT; 505 Parnassus Ave, Room M-659, San Francisco, CA 94143, Office: (415) 476-2188, Fax:
  • Dvorak CC; 505 Parnassus Ave, Room M-659, San Francisco, CA 94143, Office: (415) 476-2188, Fax:
  • Cowan MJ; 505 Parnassus Ave, Room M-659, San Francisco, CA 94143, Office: (415) 476-2188, Fax:
Curr Pediatr Rep ; 3(1): 1-10, 2015 Mar 01.
Article en En | MEDLINE | ID: mdl-25821657
Hematopoietic stem cell transplantation (HSCT) is an effective approach for the treatment of severe combined immunodeficiency (SCID). However, SCID is not a homogeneous disease, and the treatment required for successful transplantation varies significantly between SCID subtypes and the degree of HLA mismatch between the best available donor and the patient. Recent studies are beginning to more clearly define this heterogeneity and how outcomes may vary. With a more detailed understanding of SCID, new approaches can be developed to maximize immune reconstitution, while minimizing acute and long-term toxicities associated with chemotherapy conditioning.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Curr Pediatr Rep Año: 2015 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Curr Pediatr Rep Año: 2015 Tipo del documento: Article